Guilin Yang

Title: Guilin Yang: Innovator in Cell-Based Assays

Introduction

Guilin Yang is a prominent inventor based in Shenzhen, China. He has made significant contributions to the field of immunology through his innovative patent work. His research focuses on developing advanced methods for detecting toxins and cells in clinical samples.

Latest Patents

Guilin Yang holds a patent for a groundbreaking technology titled "Cell-based methods for rapid real-time assay of a presence of toxin and/or cells." This patent describes an assay that utilizes a toxin-enhancing antibody and a sensitive cell line carrying FcyR receptors. The invention includes kits for this assay, which is capable of detecting less than 1 pg/ml of toxins in clinical samples. Notably, a TcdA-specific monoclonal antibody, AIH3, was found to significantly enhance the cytotoxicity of TcdA to macrophages and monocytes. The AIH3-dependent enhancement of glucosyltransferase activity, cytoskeleton disruption, and TNF-a production induced by TcdA was demonstrated in RAW 264.7 cells. Additionally, the patent outlines methods for high-level recombinant expression of toxins in cells, along with vectors for expression and strains carrying these vectors.

Career Highlights

Guilin Yang is affiliated with Tufts University, where he continues to advance his research in the field of immunology. His work has garnered attention for its potential applications in clinical diagnostics and therapeutic development.

Collaborations

Guilin Yang has collaborated with notable colleagues, including Hanping Feng and Saul Tzipori. Their combined expertise has contributed to the advancement of research in toxin detection and immunological assays.

Conclusion

Guilin Yang's innovative work in cell-based assays represents a significant advancement in the detection of toxins and cells. His contributions to the field are poised to impact clinical diagnostics and therapeutic strategies in the future.